The launch date of Ruxolitinib Tablets/Gekway

As the first JAK1/2 inhibitor widely recognized globally, Ruxolitinib is a milestone in the treatment of blood diseases and immune-related complications. It was first approved by the U.S. Food and Drug Administration (FDA) in 2011 and is suitable for the treatment of myelofibrosis patients. This marks a new stage of oral small molecule targeted drugs in the global control of myeloproliferative diseases.

Subsequently,The European Union also approved its marketing in 2012 and entered clinical use under the trade names of Jakavi or Jakafi. In just a few years, the scope of application of ruxolitinib has continued to expand, and in 2014 it was approved for polycythemia vera. This development has given patients who originally had poor response to hydroxyurea a new treatment option. Further development occurred in 2019, when its indication was expanded to steroid-refractory acute graft-versus-host disease, marking the drug's extension from the traditional field of myelofibrosis into the key scenario of transplantation immunology, which also showed its potential in suppressing abnormal immune responses.

China ushered in the official launch of the original drug ruxolitinib in 2021, and it was quickly included in the Category B list of medical insurance and conditionally used for patients who meet the indications. This has greatly improved the accessibility of domestic patients and also reflects domestic progress in the management and protection of blood disease medication. From international to local, from a single disease to the expansion of multiple indications, the launch process of ruxolitinib is not only a timeline, but also witnesses the rapid evolution of targeted drugs in the field of precision medicine.

For patients, its advent means new treatment hope, and for clinical purposes, it also promotes the possibility of exploring the application of JAK pathway inhibitors in more diseases. In the future, with the accumulation of more real-world research data and the continuous application for new indications, ruxolitinib's marketing process may also extend to more fields, thereby bringing more personalized treatment options to the clinic.

Reference materials:https://www.jakavi.com/